FRIDAY, Aug. 18, 2023 (HealthDay News) -- Older adults with cognitive impairment have limited eligibility for anti-β amyloid monoclonal antibodies when applying clinical trial criteria, according to a study published online Aug. 16 in Neurology. Rioghna R. Pittock, from the Mayo Clinic in Rochester, Minnesota, and colleagues applied the clinical trial eligibility criteria for lecanemab